-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:AEE公佈了強勁的2026年第一季業績,稀釋後每股收益為1.28美元,高於上年同期的1.07美元,同比增長19.6%,超出華爾街預期。儘管受天氣不利因素影響,電力銷售下降,總營業收入仍成長至21.76億美元(+3.8%)。這項業績反映了基礎設施投資策略的成功實施,獲利成長主要得益於資本投資增加帶來的回報以及2025年生效的新服務費率。管理層重申了2026年每股收益預期為5.25美元至5.45美元,顯示對實現全年目標充滿信心。 Ameren Missouri業務表現突出,獲利7,600萬美元,高於2025年第一季的4,200萬美元(+81%)。資本支出飆升至15.74億美元,去年同期為10.64億美元(成長47.9%),反映出電力、天然氣和輸電資產等基礎設施投資的加速推進。強勁的第一季開局使公司在執行策略投資計畫的同時,能夠更好地實現財務目標。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.